Quallent Pharmaceuticals recalled 3,591 bottles of Duloxetine Delayed-Release Capsules on August 8, 2025. The recall stems from CGMP deviations regarding an impurity exceeding safety limits. Consumers should stop using the product immediately and contact their healthcare provider.
CGMP deviations: N-nitroso-duloxetine impurity above the proposed interim limit.
Consumers and healthcare providers should stop using this product immediately. Contact Breckenridge Pharmaceutical, Inc. or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled product is Duloxetine Delayed-Release Capsules, USP, 30 mg, with 1,000 capsules per bottle. Manufactured by Towa Pharmaceutical Europe, S.L., it is distributed in Arizona, Indiana, and New Jersey. The NDC is 82009-030-10, and the lot number is 240927C, expiring on April 30, 2027.
The recall addresses CGMP deviations, specifically the presence of N-nitroso-duloxetine impurity above the proposed interim limit. This impurity poses significant health risks, leading to a high hazard classification.
No specific incidents or injuries have been reported related to this recall. The impurity issue presents potential health risks, but actual harm to consumers remains unreported.
Stop using the recalled Duloxetine Capsules immediately. Contact Breckenridge Pharmaceutical, Inc. or your healthcare provider for further guidance and potential medication alternatives.
For more information, consumers can reach Breckenridge Pharmaceutical, Inc. through their official website or customer service line. Further details can also be found on the FDA's enforcement report page.
Get instant alerts for recalls that affect you. Free forever.
Glenmark Pharmaceuticals recalled nearly 97,000 packs of Ondansetron Orally Disintegrating Tablets on December 30, 2025. Defective blister packs may not fully seal, leading to tablets falling out. Consumers should stop using the product immediately and contact healthcare providers.
Novo Nordisk recalled Wegovy (semaglutide) injections on December 19, 2025, after discovering hair in prefilled syringes. The contamination poses a serious hazard to consumers. The recall affects all units distributed nationwide.
Novo Nordisk recalled Wegovy (semaglutide) Injection on December 19, 2025, due to hair found in a prefilled syringe. The recall affects products distributed nationwide in the United States. Consumers should stop using the product immediately and contact their healthcare provider.
Zydus Pharmaceuticals recalled over 2,100 bottles of TraZODONE Hydrochloride Tablets on December 19, 2025. Some tablets have surface dents that may affect medication integrity. Consumers should stop using the product immediately and seek guidance from healthcare providers.
CareFusion 213, LLC recalled 106,400 units of ChloraPrep Triple Swabsticks on December 17, 2025. The recall occurred due to a lack of assurance of sterility. Consumers must stop using the product immediately and contact CareFusion for guidance.
Merck Sharp & Dohme LLC recalled 845 kits of Noxafil Powdermix on December 12, 2025. The recall follows the discovery of potential metal particulates in the product. Consumers should stop using the medication immediately and contact their healthcare provider for further guidance.
Merck Sharp & Dohme LLC recalled 3 single-dose kits of Emend (aprepitant) on December 12, 2025. The recall stems from the potential presence of metal particulates in the medication. Consumers should immediately stop using the product and contact their healthcare provider for guidance.
Beaver-Visitec International recalled five units of the OME6000U Laser and Endoscopy System on December 5, 2025. The recall stems from a manufacturing deviation where ferrites required for the USB cable were not installed. This omission poses a high electrical hazard risk to patients and healthcare providers.